Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 3111


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Biotechnology
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3111

License Grant
The License Agreement was terminated and all rights under the License granted to Par reverted back to the Company under the Termination Agreement.  Under the Supply Agreement, the Company had agreed to supply all of Par’s requirements for Onconase®.  Pursuant to the Termination Agreement, Par will be entitled to a royalty of 2% of net sales of Onconase® or any other ranpirnase product developed by the Company for use in the treatment of cancer in the United States and its territories commencing with the first sale of such product and terminating upon the later to occur of the twelfth anniversary of the first sale and the date of expiration of the last valid claim of a pending application or issued patent owned or controlled by the Company with respect to such product.

Original Agreement January 2008, the Company entered into a U.S. License Agreement for Onconase® with Par Pharmaceutical, Inc. Under the terms of the License Agreement, Strativa Pharmaceuticals, the proprietary products division of Par, received exclusive marketing, sales and distribution rights to Onconase® for the treatment of cancer in the United States and its territories.  The Company retained all rights and obligations for product manufacturing, clinical development and obtaining regulatory approvals, as well as all rights for those non-U.S. jurisdictions in which the Company has not currently granted any such rights or obligations to third parties.  The Company received a cash payment of $ upon the signing of the License Agreement.

License Property
The Company has evaluated both the License Agreement and the Termination Agreement and has determined that the Company is obligated to provide royalty payments in the event the Company has net sales.  As such, as of January 31, 2011, the Company has not recognized into income any of the upfront payment received under the License Agreement.
Field of Use
Onconase® is a first-in-class therapeutic based on proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, Onconase® has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. Onconase® triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

IPSCIO Record ID: 368522

License Grant
Licensor grants the following rights and licenses
–  an exclusive license under the Licensor Patents and under any and all applicable Regulatory Approvals in the Field to promote, market, have marketed, distribute, sell, offer for sale and otherwise Commercialize Product in  the Field in the Territory and to do such other things necessary to comply with Licensees obligations under this Agreement.
–  as further provided, in order to protect the Product in the Field, an exclusive license to enforce the Licensor Patents against any potential Third Party infringement that could reasonably be expected to adversely affect the Commercialization or value of the Product in the Territory.

Licensor grants an exclusive license in the Field in the Territory, without the right to sublicense, under the Trademark and each Trade Name that has obtained or hereafter obtains Regulatory Approval for use in connection with the Product, to promote, market, offer for sale, sell and have sold Product in the Field in the Territory.

License Property
The Product means any pharmaceutical product containing Ranpirnase for parenteral administration that has been developed by Licensor or is developed by Licensor pursuant to this Agreement, including as the Product may be modified to obtain Regulatory Approval thereof, including the a generically-labeled version of the Product.

Ranpirnase means the active pharmaceutical ingredient, which may be obtained from natural sources or a recombinant source. For the sake of clarity, sequence variants, and fusion proteins and conjugates that incorporate Ranpirnase, are expressly excluded, but various formulations of the active pharmaceutical ingredient described.

Trademark means United States Trademark Reg. No. 1,651,885, covering ONCONASE as applied to pharmaceuticals; namely, cancer-treating drugs.

ONCONASE is a first-in-class product candidate based on Licensor's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Field of Use
ONCONASE is in Phase III development for the treatment of inoperable malignant mesothelioma, a rare cancer affecting the lungs usually associated with exposure to asbestos.

The Field means all uses for cancer in humans.

IPSCIO Record ID: 203

License Grant
The agreement by each Party to terminate the Agreements is conditioned upon the Parties entering into this Agreement to, among other things, set forth certain understandings with respect to the post-termination rights and obligations of each Party. The Parties agree and confirm that, except in respect of this Agreement, including the Surviving Provisions, any and all contracts, agreements and  understandings, whether written or oral, including the Agreements, are hereby terminated and are of no further force and effect.  Each of the Parties agrees that, except for the Surviving Provisions, none of the terms, conditions or obligations of such contracts, agreements and understandings shall survive termination, that all rights and licenses granted to licensee under the License Agreement shall automatically and immediately terminate and shall revert to Licensor as of the Effective Date and that this Agreement supersedes any of the terms of such contracts, agreements and understandings.
License Property
The Original License Agreement refers to the exclusive licensing agreement to acquire the U.S. commercialization rights to Onconase® (ranpirnase), then in development for the treatment of unresectable malignant mesothelioma.  The Original License Agreement was dated as of January 14, 2008.
Field of Use
The rights granted apply to the healthcare industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.